MSD acquires right to oral drench, Vecoxan
MSD Animal Health (known as Merck in the US and Canada) has closed a deal to acquire worldwide rights to Vecoxan, an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health.
Coccidiosis, a common cause of scours in lambs and calves, is a cause of significant economic loss to farmers and producers due to reduced feed conversion, growth rates and performance, and by the animals’ increased susceptibility to other infections such as intestinal disease or BRD.
Vecoxan is an anticoccidial of the benzeneacetonitrile group without antimicrobial activity and has anticoccidial activity against the Eimeria species. The product can be used in calves or lambs, beef and dairy, of any weight and in any management system without environmental restrictions. It has a zero-day meat withdrawal period.
Parasite control and prevention is an essential part of overall ruminant health management.
‘With advanced digital and diagnostic solutions to manage the welfare of animals as critical components of our technology, we are dedicated to advancing the health and well-being of animals and the people who take care f them,’ said Merck president, Rick DeLuca recently.